Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'RO-40-5967' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 145 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Villame, J; Massicotte, J; Jasmin, G; Dumont, L
      Effects of mibefradil, a T- and L-type calcium channel blocker, on cardiacremodeling in the UM-X7.1 cardiomyopathic hamster

      CARDIOVASCULAR DRUGS AND THERAPY
    2. Leuranguer, V; Mangoni, ME; Nargeot, J; Richard, S
      Inhibition of T-type and L-type calcium channels by mibefradil: Physiologic and pharmacologic bases of cardiovascular effects

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    3. Sandmann, S; Claas, R; Cleutjens, JPM; Daemen, MJAP; Unger, T
      Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    4. Sandmann, S; Bohle, RM; Dreyer, T; Unger, T
      The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats

      VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY
    5. Chung, O; Hinder, M; Sharma, AM; Bonner, G; Middeke, M; Platon, J; Unger, T
      Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-1100 mg) in mild to moderate hypertension

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    6. Tjeerdsma, G; Brouwer, J; de Kam, PJ; Haaksma, J; Crijns, HJGM; van Veldhuisen, DJ
      Effect of mibefradil on heart rate variability in patients with chronic heart failure

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    7. Murakami, M; Yamamura, H; Murakami, A; Okamura, T; Nunoki, K; Mitui-Saito, M; Muraki, K; Hano, T; Imaizumi, Y; Flockerzi, V; Yanagisawa, T
      Conserved smooth muscle contractility and blood pressure increase in response to high-salt diet in mice lacking the beta 3 subunit of the voltage-dependent calcium channel

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    8. de Curzon, OP; Ghaleh, B; Hittinger, L; Giudicelli, JF; Berdeaux, A
      Beneficial effects of the T- and L-type calcium channel antagonist, mibefradil, against exercise-induced myocardial stunning in dogs

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    9. Siepmann, M; Kirch, W
      Drug-drug interactions of new active substances: mibefradil example

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    10. Lacinova, L; Klugbauer, N; Hofmann, F
      Regulation of the calcium channel alpha(1G) subunit by divalent cations and organic blockers

      NEUROPHARMACOLOGY
    11. Jimenez, C; Bourinet, E; Leuranguer, V; Richard, S; Snutch, TP; Nargeot, J
      Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels

      NEUROPHARMACOLOGY
    12. Rinaldi, G; Navia, D; Vaccarino, G; Segura, E; Albertal, J
      Vasodilators in isolated human radial arteries.

      MEDICINA-BUENOS AIRES
    13. Martin, RL; Lee, JH; Cribbs, LL; Perez-Reyes, E; Hanck, DA
      Mibefradil block of cloned T-type calcium channels

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    14. Wu, SW; Zhang, M; Vest, PA; Bhattacharjee, A; Liu, L; Li, M
      A mibefradil metabolite is a potent intracellular blocker of L-type Ca2+ currents in pancreatic beta-cells

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    15. Gomora, JC; Xu, L; Enyeart, JA; Enyeart, JJ
      Effect of mibefradil on voltage-dependent gating and kinetics of T-type Ca2+ channels in cortisol-secreting cells

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    16. McNaughton, NCL; Warre, R; Cooper, DG; Nasir, S; Ranson, JL; Randall, A
      Potent inhibition of a recombinant low voltage-activated Ca2+ channel by SB-209712

      EUROPEAN JOURNAL OF PHARMACOLOGY
    17. du Souich, P; Besner, JG; Clozel, JP; Welker, HA; Lefebvre, M; Caille, G
      Nonlinear kinetics and pharmacologic response to mibefradil

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    18. Levine, TB; Bernink, PJLM; Caspi, A; Elkayam, U; Geltman, EM; Greenberg, B; McKenna, WJ; Ghali, JK; Giles, TD; Marmor, A; Reisin, LH; Ammon, S; Lindberg, E
      Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure - The MACH-1 study

      CIRCULATION
    19. Molderings, GJ; Likungu, J; Gothert, M
      N-type calcium channels control sympathetic neurotransmission in human heart atrium

      CIRCULATION
    20. Potocnik, SJ; Murphy, TV; Kotecha, N; Hill, MA
      Effects of mibefradil and nifedipine on arteriolar myogenic responsivenessand intracellular Ca2+

      BRITISH JOURNAL OF PHARMACOLOGY
    21. Masumiya, H; Kase, J; Tanaka, Y; Tanaka, H; Shigenobu, K
      Effects of mibefradil, a selective T-type Ca2+ channel antagonist, on sino-atrial node and ventricular myocardia

      RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY
    22. Pinto, JMB; Sosunov, EA; Gainullin, RZ; Rosen, MR; Boyden, PA
      Effects of mibefradil, a T-type calcium current antagonist, on electrophysiology of Purkinje fibers that survived in the infarcted canine heart

      JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
    23. Paquette, F; Jasmin, G; Dumont, L
      Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters

      CARDIOVASCULAR DRUGS AND THERAPY
    24. Mocanu, MM; Gadgil, S; Yellon, DM; Baxter, GF
      Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism

      CARDIOVASCULAR DRUGS AND THERAPY
    25. van der Lee, R; Pfaffendorf, M; van Zwieten, PA
      Comparative effects of mibefradil and other calcium antagonists on resistance arteries of different end organs

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    26. Peters, J; Welker, HA; Bullingham, R
      Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses

      EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    27. Prueksaritanont, T; Ma, B; Tang, CY; Meng, Y; Assang, C; Lu, P; Reider, PJ; Lin, JH; Baillie, TA
      Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    28. Avdonin, PV; Buhler, FR; Tkachuk, VA
      Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967)

      BIOLOGICHESKIE MEMBRANY
    29. Krayenbuhl, JC; Vozeh, S; Kondo-Oestreicher, M; Dayer, P
      Drug-drug interactions of new active substances: mibefradil example

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    30. Niespodziany, I; Derambure, P; Poulain, P
      Properties of T-type calcium current in enkephalinergic neurones in guinea-pig hypothalamic slices

      PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
    31. Gomora, JC; Enyeart, JA; Enyeart, JJ
      Mibefradil potently blocks ATP-activated K+ channels in adrenal cells

      MOLECULAR PHARMACOLOGY
    32. Min, JY; Sandmann, S; Meissner, A; Unger, T; Simon, R
      Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca2+ handling in rats with chronic myocardial infarction

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    33. Reimer, KA; Califf, RM
      Good news for experimental concept but bad news for clinically effective therapy

      CIRCULATION
    34. Sandmann, S; Min, JY; Meissner, A; Unger, T
      Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca2+-handling in infarct-induced heart failure in rats

      CARDIOVASCULAR RESEARCH
    35. Liu, JH; Bijlenga, P; Occhiodoro, T; Fischer-Lougheed, J; Bader, CR; Bernheim, L
      Mibefradil (Ro40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts

      BRITISH JOURNAL OF PHARMACOLOGY
    36. BILLUPS SJ; CARTER BL
      MIBEFRADIL - A NEW CLASS OF CALCIUM-CHANNEL ANTAGONISTS

      The Annals of pharmacotherapy
    37. SPOENDLIN M; PETERS J; WELKER H; BOCK A; THIEL G
      PHARMACOKINETIC INTERACTION BETWEEN ORAL CYCLOSPORINE AND MIBEFRADIL IN STABILIZED POST-RENAL-TRANSPLANT PATIENTS

      Nephrology, dialysis, transplantation
    38. Emanuel, K; Mackiewicz, U; Pytkowski, B; Lewartowski, B
      Effects of mibefradil, a blocker of T-type Ca2+ channels, in single myocytes and intact muscle of guinea-pig heart

      JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
    39. VANDERLEE R; KAM KL; PFAFFENDORF M; VANZWIETEN PA
      DIFFERENTIAL TIME-COURSE OF THE VASODILATOR ACTION OF VARIOUS CALCIUM-ANTAGONISTS

      Fundamental and clinical pharmacology
    40. MULLER CA; OPIE LH; MCCARTHY J; HOFMANN D; PINEDA CA; PEISACH M
      EFFECTS OF MIBEFRADIL, A NOVEL CALCIUM-CHANNEL BLOCKING-AGENT WITH T-TYPE ACTIVITY, IN ACUTE EXPERIMENTAL MYOCARDIAL-ISCHEMIA - MAINTENANCEOF VENTRICULAR-FIBRILLATION THRESHOLD WITHOUT INOTROPIC COMPROMISE

      Journal of the American College of Cardiology
    41. WOITTIEZ AJJ; HUYSMANS FTM; BAILEY R; ROBSON RA; MION D; VILLA G; KOBRIN I
      A COMPARISON OF THE SAFETY AND EFFICACY OF MIBEFRADIL AND NIFEDIPINE SR IN PATIENTS WITH RENAL-DISEASE AND HYPERTENSION

      Clinical nephrology
    42. ERNST ME; KELLY MW
      MIBEFRADIL, A PHARMACOLOGICALLY DISTINCT CALCIUM-ANTAGONIST

      Pharmacotherapy
    43. LACOLLEY P; POITEVIN P; KOEN R; LEVY BI
      DIFFERENT EFFECTS OF CALCIUM-ANTAGONISTS ON FLUID FILTRATION OF LARGEARTERIES AND ALBUMIN PERMEABILITY IN SPONTANEOUSLY HYPERTENSIVE RATS

      Journal of hypertension
    44. FRISHMAN WH; BITTAR N; GLASSER S; HABIB G; SMITH W; PORDY R
      ADDITIONAL ANTIANGINAL AND ANTIISCHEMIC EFFICACY OF MIBEFRADIL IN PATIENTS CONCOMITANTLY TREATED WITH LONG-ACTING NITRATES FOR CHRONIC STABLE ANGINA-PECTORIS

      Clinical cardiology
    45. HOISCHEN S; BRIXIUS K; SCHWINGER RHG
      T-TYPE AND L-TYPE CA2-CHANNEL ANTAGONISTS REDUCE CONTRACTILITY IN GUINEA-PIG CARDIAC MYOCYTES()

      Journal of cardiovascular pharmacology
    46. GLASSER SP
      THE RELEVANCE OF T-TYPE CALCIUM-ANTAGONISTS - A PROFILE OF MIBEFRADIL

      Journal of clinical pharmacology
    47. Heitmann, J; Grote, L; Knaack, L; Kohler, U; Hinder, M; Peter, JH
      Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    48. ARNOULT C; VILLAZ M; FLORMAN HM
      PHARMACOLOGICAL PROPERTIES OF THE T-TYPE CA2+ CURRENT OF MOUSE SPERMATOGENIC CELLS

      Molecular pharmacology
    49. McDonough, SI; Bean, BP
      Mibefradil inhibition of T-type calcium channels in cerebellar Purkinje neurons

      MOLECULAR PHARMACOLOGY
    50. SHIMOYAMA H; SABBAH HN; TANIMURA M; BORZAK S; GOLDSTEIN S
      SHORT-TERM HEMODYNAMIC-EFFECTS OF MIBEFRADIL IN DOGS WITH CHRONIC HEART-FAILURE - COMPARISON WITH DILTIAZEM

      The Journal of pharmacology and experimental therapeutics
    51. Rossier, MF; Ertel, EA; Vallotton, MB; Capponi, AM
      Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    52. SILLIMAN CC; VOELKEL NF; ALLARD JD; ELZI DJ; TUDER RM; JOHNSON JL; AMBRUSO DR
      PLASMA AND LIPIDS FROM STORED PACKED RED-BLOOD-CELLS CAUSE ACUTE LUNGINJURY IN AN ANIMAL-MODEL

      The Journal of clinical investigation
    53. BLAHETA RA; HAILER NP; BRUDE N; WITTIG B; OPPERMANN E; LECKEL K; HARDER S; SCHOLZ M; WEBER S; ENCKE A; MARKUS BH
      NOVEL MODE OF ACTION OF THE CALCIUM-ANTAGONIST MIBEFRADIL (RO-40-5967) - POTENT IMMUNOSUPPRESSION BY INHIBITION OF T-CELL INFILTRATION THROUGH ALLOGENEIC ENDOTHELIUM

      Immunology
    54. LAM E; SKARSGARD P; LAHER I
      INHIBITION OF MYOGENIC TONE BY MIBEFRADIL IN RAT CEREBRAL-ARTERIES

      European journal of pharmacology
    55. VANDERVRING JA; CLEOPHAS TJ; VANDERWALL EE; NIEMEYER MG
      T-CHANNEL SELECTIVE CALCIUM-CHANNEL BLOCKADE - A REVIEW OF PUBLISHED DATA AND THERAPEUTIC POTENTIAL

      Current therapeutic research
    56. CRIBBS LL; LEE JH; YANG J; SATIN J; ZHANG Y; DAUD A; BARCLAY J; WILLIAMSON MP; FOX M; REES M; PEREZREYES E
      CLONING AND CHARACTERIZATION OF ALPHA-1H FROM HUMAN HEART, A MEMBER OF THE T-TYPE CA2+ CHANNEL GENE FAMILY

      Circulation research
    57. SANDMANN S; SPITZNAGEL H; CHUNG O; XIA QG; ILLNER S; JANICHEN G; ROSSIUS B; DAEMEN MJAP; UNGER T
      EFFECTS OF THE CALCIUM-CHANNEL ANTAGONIST MIBEFRADIL ON HEMODYNAMIC AND MORPHOLOGICAL PARAMETERS IN MYOCARDIAL INFARCTION-INDUCED CARDIAC-FAILURE IN RATS

      Cardiovascular Research
    58. HOGLUND C; CIFKOVA R; MIMRAN A; TENCZER J; WATT A; WILKINS MR; LINDBERG E
      A COMPARISON OF THE EFFECTS OF MIBEFRADIL AND ATENOLOL ON REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS

      Cardiology
    59. HERMSMEYER K
      ROLE OF T-CHANNELS IN CARDIOVASCULAR FUNCTION

      Cardiology
    60. NOLL G; LUSCHER TF
      COMPARATIVE PHARMACOLOGICAL PROPERTIES AMONG CALCIUM-CHANNEL BLOCKERS- T-CHANNEL VERSES L-CHANNEL BLOCKADE

      Cardiology
    61. KOBRIN I; BIESKA G; CHARLON V; LINDBERG E; PORDY R
      ANTIANGINAL AND ANTIISCHEMIC EFFECTS OF MIBEFRADIL, A NEW T-TYPE CALCIUM-CHANNEL ANTAGONIST

      Cardiology
    62. MULDER P; RICHARD V; THUILLEZ C
      DIFFERENT EFFECTS OF CALCIUM-ANTAGONISTS IN A RAT MODEL OF HEART-FAILURE

      Cardiology
    63. ACZEL S; KURKA B; HERING S
      MECHANISM OF VOLTAGE-DEPENDENT AND USE-DEPENDENT BLOCK OF CLASS-A CA2+ CHANNELS BY MIBEFRADIL

      British Journal of Pharmacology
    64. BRIXIUS K; MOHR V; MULLEREHMSEN J; HOISCHEN S; MUNCH G; SCHWINGER RHG
      POTENT VASODILATORY WITH MINOR CARDIODEPRESSANT ACTIONS OF MIBEFRADILIN HUMAN CARDIAC TISSUE

      British Journal of Pharmacology
    65. WAGNER C; KRAMER BK; HINDER M; KIENINGER M; KURTZ A
      T-TYPE AND L-TYPE CALCIUM-CHANNEL BLOCKERS EXERT OPPOSITE EFFECTS ON RENIN SECRETION AND RENIN GENE-EXPRESSION IN CONSCIOUS RATS

      British Journal of Pharmacology
    66. MASON RP; MAK IT; WALTER MF; TULENKO TN; MASON PE
      ANTIOXIDANT AND CYTOPROTECTIVE ACTIVITIES OF THE CALCIUM-CHANNEL BLOCKER MIBEFRADIL

      Biochemical pharmacology
    67. PRATT CM
      IMPACT AT MANAGED CARE ON THE TREATMENT OF ATRIAL-FIBRILLATION

      The American journal of cardiology
    68. SCHNEEWEISS A; KOBRIN I; CHARLON V; CASPI A; MARMOR A; SCLAROVSKY S; REISIN L; SCHLESINGER Z
      ADDING THE NEW CALCIUM-ANTAGONIST MIBEFRADIL TO PATIENTS RECEIVING LONG-TERM BETA-BLOCKER THERAPY RESULTS IN IMPROVED ANTIANGINAL AND ANTIISCHEMIC EFFICACY

      The American heart journal
    69. CHARLON V; KOBRIN I
      THE EFFICACY AND SAFETY OF MIBEFRADIL IN SUBGROUPS OF PATIENTS WITH CHRONIC STABLE ANGINA-PECTORIS

      International journal of clinical practice
    70. DUNN A; CHOW MSS
      FOCUS ON MIBEFRADIL - A NOVEL SELECTIVE T-TYPE CALCIUM-CHANNEL BLOCKER

      Formulary
    71. CARNEY S; WING L; RIBEIRO A; KALLWELLIS R; ZIMLICHMAN R; VISKOPER RJ; MION D; KOBRIN I
      THE ADDITION OF MIBEFRADIL TO CHRONIC HYDROCHLOROTHIAZIDE THERAPY IN HYPERTENSIVE PATIENTS IS ASSOCIATED WITH A SIGNIFICANT ANTIHYPERTENSIVE EFFECT

      Journal of human hypertension
    72. VISKOPER RJ; BERNINK PJLM; SCHELLING A; RIBEIRO AB; KANTOLA IM; WILKINS MR; KOBRIN I
      A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING MIBEFRADIL AND AMLODIPINE - 2 LONG-ACTING CALCIUM-ANTAGONISTS WITH SIMILAR EFFICACY BUT DIFFERENT TOLERABILITY PROFILES

      Journal of human hypertension
    73. TANGUAY M; JASMIN G; BLAISE G; DUMONT L
      CORONARY AND CARDIAC SENSITIVITY TO THE VASOSELECTIVE BENZOTHIAZEPINE-LIKE CALCIUM-ANTAGONIST, CLENTIAZEM, IN EXPERIMENTAL HEART-FAILURE

      Cardiovascular drugs and therapy
    74. OPARIL S; KOBRIN I; ABERNETHY DR; LEVINE BS; REIF MC; SHEPHERD AM
      DOSE-RESPONSE CHARACTERISTICS OF MIBEFRADIL, A NOVEL CALCIUM-ANTAGONIST, IN THE TREATMENT OF ESSENTIAL-HYPERTENSION

      American journal of hypertension
    75. LACOURCIERE Y; POIRIER L; LEFEBVRE J; ARCHAMBAULT F; AVE SD; WARD C; LINDBERG E
      THE ANTIHYPERTENSIVE EFFICACY OF THE NOVEL CALCIUM-ANTAGONIST MIBEFRADIL IN COMPARISON WITH NIFEDIPINE GITS IN MODERATE TO SEVERE HYPERTENSIVES WITH AMBULATORY HYPERTENSION

      American journal of hypertension
    76. MULDER P; RICHARD V; COMPAGNON P; HENRY JP; LALLEMAND F; CLOZEL JP; KOEN R; MACE B; THUILLEZ C
      INCREASED SURVIVAL AFTER LONG-TERM TREATMENT WITH MIBEFRADIL, A SELECTIVE T-CHANNEL CALCIUM-ANTAGONIST, IN HEART-FAILURE

      Journal of the American College of Cardiology
    77. BUHLER FR
      CARDIOVASCULAR CARE WITH THE NEW T-TYPE CALCIUM-CHANNEL ANTAGONIST - POSSIBLE ROLE OF ATTENDANT SYMPATHETIC NERVOUS-SYSTEM INHIBITION

      Journal of hypertension
    78. TRIGGLE DJ
      CARDIOVASCULAR T-TYPE CALCIUM CHANNELS - PHYSIOLOGICAL AND PHARMACOLOGICAL SIGNIFICANCE

      Journal of hypertension
    79. CLOZEL JP; ERTEL EA; ERTEL SI
      DISCOVERY AND MAIN PHARMACOLOGICAL PROPERTIES OF MIBEFRADIL (RO-40-5967), THE FIRST SELECTIVE T-TYPE CALCIUM-CHANNEL BLOCKER

      Journal of hypertension
    80. KOBRIN I
      DIFFERENTIAL PROPERTIES OF MIBEFRADIL IN HYPERTENSION AND ANGINA

      Journal of hypertension
    81. HERMSMEYER K; MIYAGAWA K
      NOVEL CONCEPTS IN CA2+ CHANNEL SELECTIVITY

      Journal of hypertension
    82. LUSCHER TF; CLOZEL JP; NOLL G
      PHARMACOLOGY OF THE CALCIUM-ANTAGONIST MIBEFRADIL

      Journal of hypertension
    83. KOBRIN I; CHARLON V
      PREDICTABLE CLINICAL EFFECTS IN THE TREATMENT OF HYPERTENSION AND CHRONIC, STABLE ANGINA-PECTORIS - CLINICAL-STUDIES OF MIBEFRADIL

      Journal of hypertension
    84. MASSIE BM; CHRYSANT SG; JAIN A; WEIR M; WEISS R; KOBRIN I
      ANTIHYPERTENSIVE EFFECTS OF MIBEFRADIL - A DOUBLE-BLIND COMPARISON WITH DILTIAZEM-CD

      Clinical cardiology
    85. LEVINE TB
      THE DESIGN OF THE MORTALITY ASSESSMENT IN CONGESTIVE-HEART-FAILURE TRIAL (MACH-1, MIBEFRADIL)

      Clinical cardiology
    86. CREMERS B; FLESCH M; SUDKAMP M; BOHM M
      EFFECTS OF THE NOVEL T-TYPE CALCIUM-CHANNEL ANTAGONIST MIBEFRADIL ON HUMAN MYOCARDIAL-CONTRACTILITY IN COMPARISON WITH NIFEDIPINE AND VERAPAMIL

      Journal of cardiovascular pharmacology
    87. KARCH FE; PORDY R; BENZ JR; CARR A; LUNDE NM; MARBURY T; TARRO JN
      COMPARATIVE EFFICACY AND TOLERABILITY OF 2 LONG-ACTING CALCIUM-ANTAGONISTS, MIBEFRADIL AND AMLODIPINE, IN ESSENTIAL-HYPERTENSION

      Clinical therapeutics
    88. BITTAR N
      COMPARATIVE ANTIHYPERTENSIVE EFFECTIVENESS OF ONCE-DAILY MIBEFRADIL AND DILTIAZEM-CD

      Clinical therapeutics
    89. PITT B
      DIVERSITY OF CALCIUM-ANTAGONISTS

      Clinical therapeutics
    90. HERMSMEYER K; MISHRA S; MIYAGAWA K; MINSHALL R
      PHYSIOLOGICAL AND PATHOPHYSIOLOGIC RELEVANCE OF T-TYPE CALCIUM-ION CHANNELS - POTENTIAL INDICATIONS FOR T-TYPE CALCIUM-ANTAGONISTS

      Clinical therapeutics
    91. HABIB G
      REAPPRAISAL OF THE IMPORTANCE OF HEART-RATE AS A RISK FACTOR FOR CARDIOVASCULAR MORBIDITY AND MORTALITY

      Clinical therapeutics
    92. POOL PE
      THE CLINICAL-SIGNIFICANCE OF NEUROHORMONAL ACTIVATION

      Clinical therapeutics
    93. KATZ S
      SAFETY OF CALCIUM-ANTAGONISTS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE

      Clinical therapeutics
    94. VIANA F; VANDENBOSCH L; MISSIAEN L; VANDENBERGHE W; DROOGMANS G; NILIUS B; ROBBERECHT W
      MIBEFRADIL (RO-40-5967) BLOCKS MULTIPLE TYPES OF VOLTAGE-GATED CALCIUM CHANNELS IN CULTURED RAT SPINAL MOTONEURONS

      Cell calcium
    95. WILTSHIRE HR; SUTTON BM; HEEPS G; BETTY AM; ANGUS DW; MADIGAN MJ; SHARP SR
      METABOLISM OF THE CALCIUM-ANTAGONIST, MIBEFRADIL (POSICOR(TM), RO-40-5967) .2. METABOLISM IN HEPATIC MICROSOMES FROM RAT, MARMOSET, CYNOMOLGUS MONKEY, RABBIT AND MAN

      Xenobiotica
    96. WILTSHIRE HR; SUTTON BM; HEEPS G; BETTY AM; ANGUS DW; HARRIS SR; WORTH E; WELKER HA
      METABOLISM OF THE CALCIUM-ANTAGONIST, MIBEFRADIL (POSICOR(TM), RO 40-5967) .3. COMPARATIVE PHARMACOKINETICS OF MIBEFRADIL AND ITS MAJOR METABOLITES IN RAT, MARMOSET, CYNOMOLGUS MONKEY AND MAN

      Xenobiotica
    97. ROSENQUIST M; BREMBILLAPERROT B; MEINERTZ T; NEUGEBAUER A; CRIJNS HJMG; SMEETS JLRM; VANDERVRING JAFM; FROMER M; KOBRIN I
      THE ACUTE EFFECTS OF INTRAVENOUSLY ADMINISTERED MIBEFRADIL, A NEW CALCIUM-ANTAGONIST, ON THE ELECTROPHYSIOLOGIC CHARACTERISTICS OF THE HUMAN HEART

      European Journal of Clinical Pharmacology
    98. RANDALL AD; TSIEN RW
      CONTRASTING BIOPHYSICAL AND PHARMACOLOGICAL PROPERTIES OF T-TYPE AND R-TYPE CALCIUM CHANNELS

      Neuropharmacology
    99. GOTHERT M; MOLDERINGS GJ
      MIBEFRADIL-CONOTOXIN AND OMEGA-CONOTOXIN GVIA-INDUCED INHIBITION OF NORADRENALINE RELEASE FROM THE SYMPATHETIC-NERVES OF THE HUMAN HEART

      Naunyn-Schmiedeberg's archives of pharmacology
    100. KOBRIN I; CHARLON V; LINDBERG E; NEUMANN N; PORDY R
      MIBEFRADIL - A NEW T-CHANNEL SELECTIVE CALCIUM-ANTAGONIST

      Medicamentos de actualidad


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/08/20 alle ore 01:20:21